Moderna To $165? Plus This Analyst Cuts PT On FedEx

Deutsche Bank raised the price target on Moderna, Inc. (NASDAQ: MRNA) from $155 to $165. Deutsche Bank analyst Emmanuel Papadakis also upgraded the stock from Hold to Buy. Moderna shares rose 2.8% to trade at $138.70 on Thursday.
  • Deutsche Bank raised the price target on Moderna, Inc. (NASDAQ:MRNA) from $155 to $165. Deutsche Bank analyst Emmanuel Papadakis also upgraded the stock from Hold to Buy. Moderna shares rose 2.8% to trade at $138.70 on Thursday.
  • Wedbush lowered the price target for Verint Systems Inc. (NASDAQ:VRNT) from $65 to $56. Wedbush analyst Daniel Ives maintained the stock with a Outperform. Verint shares fell 9.9% to $40.94 on Thursday.
  • Wells Fargo reduced the price target on Toast, Inc. (NYSE:TOST) from $27 to $23. Toast shares rose 0.5% to $19.18 in pre-market trading.
  • Wells Fargo cut the price target for FedEx Corporation (NYSE:FDX) from $282 to $269. FedEx shares fell 1.2% to $199.23 on Thursday.
  • Citigroup cut the price target on American Eagle Outfitters, Inc. (NYSE:AEO) from $13 to $10. American Eagle shares fell 11.5% to $10.26 in pre-market trading.
  • Goldman Sachs boosted the price target for Enphase Energy, Inc. (NASDAQ:ENPH) from $290 to $328. Enphase Energy shares rose 1.8% to $321.84 on Thursday.
  • Stifel raised the price target on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) from $60 to $65. Apellis Pharmaceuticals shares jumped 1.7% to $65.32 on Thursday.

Check out this: Volatility In Markets Decreases After Dow Surges Over 400 Points

Total
0
Shares
Related Posts
Read More

Braxia Scientific Q2 2023 Financial Results: Health Clinic Ketamine Treatments Increases 34.5% YoY

Braxia Scientific Corp., (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, announced the filing of its financial statements and management discussion and analysis for the

BRAXF